Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
105 hedge funds and large institutions have $310M invested in Astria Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 24 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $311M → $310M (-$1.55M)
1.37% less ownership
Funds ownership: 103.35% → 101.98% (-1.4%)
9% less funds holding
Funds holding: 115 → 105 (-10)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$8.05M |
| 2 |
Millennium Management
New York
|
+$6.47M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.7M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.94M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$27.3M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.58M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.32M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.9M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.44M |
ATXS Hedge Fund Activity: Q2 2025 in Review
105 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2025, worth a combined $310M — down 0.5% from $311M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATXS and 14 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 44 added.
The largest buyer was JP Morgan Chase, adding an estimated $8.05M. The largest seller was RA Capital Management, exiting entirely with an estimated $27.3M sold.
- 105 institutional investors held Astria Therapeutics (ATXS) as of Q2 2025, down from 115 in Q1 2025.
- Funds reported $310M of Astria Therapeutics stock for Q2 2025, down 0.5% quarter-over-quarter.
- 14 funds opened new Astria Therapeutics positions in Q2 2025 and 24 closed out, a net change of -10 holders.
- The largest Astria Therapeutics buyer in Q2 2025 was JP Morgan Chase, an estimated $8.05M added.
- The largest Astria Therapeutics seller in Q2 2025 was RA Capital Management, an estimated $27.3M sold.
Based on aggregated 13F filings for Q2 2025.